They are starting to work in humans Read the last few sentences
Presentation Abstract
Program#/Poster#: 202.11
Presentation Title: Two year plasma lipidomic profile in a mouse model of single and repetitive mild Traumatic Brain Injury
Location: WCC 152A
Presentation time: Sunday, Nov 16, 2014, 3:30 PM - 3:45 PM
Topic: ++C.10.b. Brain: Animal models
Authors: *F. C. CRAWFORD1,2,3, B. MOUZON1,2,3, T. EMMERICH1,3, L. ABDULLAH1,4, J. EVANS1,2, J. M. REED1,2, G. C. CRYNEN1,2, M. J. MULLAN1,2,3;
1Roskamp Inst., SARASOTA, FL; 2James A. Haley Veterans' Hosp., Tampa, FL; 3The Open Univ., Milton Keynes, United Kingdom; 4James A. Haley Veterns' Hosp., Tampa, FL
Abstract: Traumatic brain injury (TBI), in particular mild TBI (mTBI) is a major problem for both military and civilian populations. An objective panel of biomarkers for TBI and related conditions would enable appropriate medical management, may indicate ongoing pathogenic processes, provide guidance in therapeutic development, and could be used to monitor outcome and response to treatment. We have developed a mouse model of single and repetitive mTBI that shows progressive neuroflammation and neurobehavioral changes, characterized through to 2 years post injury. Phospholipids (PLs) such as phosphatidylcholine (PC) and sphingomyelin (SM), play a prominent role in neuronal processes including neurotransmitter release, neurite outgrowth and synaptogenesis, and brain lipid metabolism is disrupted in our preclinical TBI models. We have used our lipidomic platform (in-source collision induced dissociation (sCID) with full scan liquid chromatography/MS (LC/MS)) to generate a temporal profile of plasma lipidomic changes in our mouse model. Plasma profiling demonstrates significant TBI-dependent changes in lipid profiles that persist years after the injury, including significant increases in PC and SM. To determine the clinical relevance of these findings we will correlate plasma lipidomic changes with brain lipidomic changes in this model, but we are also validating our findings by investigating plasma lipid profiles in human TBI populations. Funding CDMRP funding (Crawford W81XWH-10-1-0759), and VA Merit funding (Crawford); and the Roskamp Foundation.
Disclosures: F.C. Crawford: None. B. Mouzon: None. T. Emmerich: None. L. Abdullah: None. J. Evans: None. J.M. Reed: None. G.C. Crynen: None. M.J. Mullan: None.
Keyword (s): TRAUMATIC BRAIN INJURY
LIPID
ANIMAL MODEL
Support: CDMRP funding (Crawford W81XWH-10-1-0759)
VA Merit funding (Crawford)
the Roskamp Foundation
AI
